1,25-Dihydroxyvitamin D3decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat
- 1 March 2004
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 286 (3), F526-F533
- https://doi.org/10.1152/ajprenal.00316.2003
Abstract
1,25(OH)2D3has antiproliferative effects and promotes cell differentiation. This consideration has provided the rationale for studies in subtotally nephrectomized rats showing that 1,25(OH)2D3interferred with glomerulosclerosis. The cellular mechanisms involved have remained obscure, however. It was the purpose of the present study to assess glomerular structure and cellular composition in subtotally nephrectomized (SNX) rats treated with nonpharmacological doses of 1,25(OH)2D3. Male Sprague-Dawley rats were sham operated (sham) or underwent SNX under general anesthesia and received either solvent or 1,25(OH)2D3(3 ng·100 g body wt-1·day-1sc). Blood pressure (BP) and albuminuria were measured. After 16 wk, the remnant renal tissue was perfusion fixed and morphometric and stereological measurements were carried out. The expression of proliferating cellular antigen (PCNA), cyclin-dependent kinase inhibitor p27, Wilms tumor gene (WT1), and desmin, a marker of early podocyte damage, was investigated by immunohistology. BP, serum creatinine, and urinary albumin excretion were significantly higher in SNX than in sham rats. Albuminuria was significantly lower in SNX+1,25(OH)2D3compared with SNX+solvent rats. Mean glomerular tuft volume was significantly higher in SNX+solvent (2.69 ± 0.21 g× 106μm3) than in sham rats (1.44 ± 0.17 and 1.28 ± 0.14 × 106μm3); it was significantly ( P < 0.05) lower in SNX+1,25(OH)2D3rats (1.81 ± 0.16 × 106μm3). The main finding was a significantly higher number of podocytes in SNX+1,25(OH)2D3(88 ± 9) and sham (98 ± 17) compared with SNX+solvent rats (81 ± 8.7). In parallel, the increase in podocyte volume in SNX+solvent rats was abrogated by treatment with 1,25(OH)2D3, and immunohistochemistry revealed less expression of desmin, PCNA, and p27, suggesting less podocyte injury and activation of the cyclin cascade. This study identifies the podocyte as an important target cell for the renoprotective action of 1,25(OH)2D3. This notion is suggested by less evidence of podocyte injury, decreased podocytes loss, and abrogation of podocyte hypertrophy, findings that may also explain less pronounced albuminuria and glomerulosclerosis.Keywords
This publication has 45 references indexed in Scilit:
- ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathyDiabetologia, 2003
- Urinary Podocytes in Primary Focal Segmental GlomerulosclerosisNephron, 2001
- 1,25(OH)2Vitamin D3Induces Elevated Expression of the Cell Cycle-regulating Genes P21 and P27 in Squamous Carcinoma Cell Lines of the Head and NeckActa Oto-Laryngologica, 2001
- Altering expression of α3β1 integrin on podocytes of human and rats with diabetesLife Sciences, 2000
- Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetesKidney International, 2000
- Vitamin D3 inhibits proliferation and increases c-myc expression in fibroblasts from psoriatic patients.Journal of Endocrinological Investigation, 1998
- Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failureNephrology Dialysis Transplantation, 1996
- Partial prevention of active Heymann nephritis by 1α, 25 dihydroxyvitamin D3Clinical and Experimental Immunology, 1993
- Adhesion of rat glomerular epithelial cells to extracellular matrices: Role of β1 integrinsKidney International, 1992
- Stereology of arbitrary particles*Journal of Microscopy, 1986